caa a22 4500 465794459 CHVBK 20180323112033.0 cr unu---uuuuu 170327e19901001xx s 000 0 eng 10.1007/BF00164834 doi (NATIONALLICENCE)springer-10.1007/BF00164834 Decrease in adverse reactions after repeated ivermectin treatment in onchocerciasis [Elektronische Daten] [A. Van Der Lelij, A. Rothova, N. Klaassen-Broekema, W. Wilson, R. Barbe, J. Stilma] We assessed the side-effects after multiple single-dose treatment with ivermectin (150μg/kg) in onchocerciasis patients from a hyperendemic area in Sierra Leone, in order to investigate whether medical surveillance was always necessary. After initial treatment 87 onchocerciasis patients were examined for adverse reactions. Fourty-four of these 87 patients (51%) received a second dose of invermectin 5 months later and thirty-five (40%) received a third dose one year later. The side-effects after the second and third doses were significantly diminished, when compared with the initial dose of ivermectin in the treatment of onchocerciasis (χ 2 test p < 0.005, resp. p < 0.008). Side-effects requiring therapy were observed in 32% of patients after the first dose, in 18% after the second dose and in 11% after the third dose of ivermectin. Severe side-effects (9%) were only seen after the initial ivermectin dose. All the severe adverse reactions appeared within 48 hours. In view of our findings, it seems necessary that the first treatment with invermectin should take place under strict medical supervision during at least two days. Five months after treatment with a single dose of invermectin 29 out of 44 patients (66%) still had a positive skin-snip test. Seven months after the second dose 15 of 35 patients (43%) had a positive skin-snip count. Since almost half of the patients had a positive skin-snip test despite two treatments with ivermectin, it could be argued that in hyperendemic areas treatment should consist of at least two doses in the first year. Kluwer Academic Publishers, 1990 Onchocerciasis nationallicence ivermectin nationallicence side-effects nationallicence Van Der Lelij A. Department of Ophthalmology, Free University Amsterdam, Amsterdam, The Netherlands aut Rothova A. Department of Ophthalmology, University of Amsterdam, Amsterdam, The Netherlands aut Klaassen-Broekema N. F.C. Danders Institute of Ophthalmology, Utrecht, The Netherlands aut Wilson W. Eye Hospital Lunsar, Sierra Leone, West Africa aut Barbe R. Eye Hospital Lunsar, Sierra Leone, West Africa aut Stilma J. F.C. Danders Institute of Ophthalmology, Utrecht, The Netherlands aut Documenta Ophthalmologica Kluwer Academic Publishers 75/3-4(1990-10-01), 215-224 0012-4486 75:3-4<215 1990 75 10633 https://doi.org/10.1007/BF00164834 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00164834 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Van Der Lelij A. Department of Ophthalmology, Free University Amsterdam, Amsterdam, The Netherlands aut NATIONALLICENCE 700 1- Rothova A. Department of Ophthalmology, University of Amsterdam, Amsterdam, The Netherlands aut NATIONALLICENCE 700 1- Klaassen-Broekema N. F.C. Danders Institute of Ophthalmology, Utrecht, The Netherlands aut NATIONALLICENCE 700 1- Wilson W. Eye Hospital Lunsar, Sierra Leone, West Africa aut NATIONALLICENCE 700 1- Barbe R. Eye Hospital Lunsar, Sierra Leone, West Africa aut NATIONALLICENCE 700 1- Stilma J. F.C. Danders Institute of Ophthalmology, Utrecht, The Netherlands aut NATIONALLICENCE 773 0- Documenta Ophthalmologica Kluwer Academic Publishers 75/3-4(1990-10-01), 215-224 0012-4486 75:3-4<215 1990 75 10633 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer